In new research published in the New England Journal of Medicine, investigators led by William Tamborlane, M.D., a Yale University pediatric endocrinologist, reported the efficacy of the GLP1 agonist liraglutide for children with type 2 diabetes. In this Q&A, Dr. Tamborlane discusses the importance of expanding treatment options.
Men with diabetes may have a higher risk of experiencing chronic lower back pain, say researchers writing in BMJ Open this month.
Normal thyroid stimulating hormone levels don't necessarily stave off all-cause mortality for hypothyroid patients, but adverse outcomes may intensify if levels fall below or above the norm.
Estrogen-based hormone therapy may not be associated with reduced loss of lean body mass compared with no hormone therapy in postmenopausal women, find researchers writing in JAMA Network Open last month.
A 60-year-old woman undergoing hemodialysis for chronic kidney disease visited her physician with concerns about a painful smooth plaque on her leg that developed over the last few weeks. What's your diagnosis?
A lot has changed over the course of 10 years in solo practice, writes Melissa Young, M.D., in this month's Endocrine Feedback column. Dr. Young describes a decade of changes for the solo endocrinology practitioner.
Metformin as monotherapy is the preferred treatment for children and teens with type 2 diabetes, but a new study published in the Aug. 15 issue of the New England Journal of Medicine suggests that adding liraglutide to the treatment can more effectively control glycemic levels.
A single course of treatment with teplizumab significantly slowed the progression of type 1 diabetes in high-risk individuals who had not yet deveoped the condition, according to a study in the New England Journal of Medicine.
Stimulating the sphenopalatine ganglion—a collection of nerve cells closely associated with the trigeminal nerve most responsible for headaches—could be a safe intervention for patients with acute ischemic stroke who aren’t eligible for thrombolytic therapy, researchers report in The Lancet.
Awareness of the prevalence of hypertension has increased substantially over the past 40 years in high-income countries, as has treatment and control of the condition. But, the level of control falls short of rates seen in dedicated hypertension programs, and it’s stagnating, according to research published last month in The Lancet.